Artivion announces agreements to exchange $95 million in principal amount of its 4.250% convertible notes due 2025 for common stock

Atlanta , may 14, 2025 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% convertible senior notes due 2025 (the "existing convertible notes"). under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of existing convertible notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on may 15, 2025 (the "shares").
AORT Ratings Summary
AORT Quant Ranking